Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial

Table 1 Patients' baseline characteristics

	T ≤ -2, A+R (n = 93)		-2 < T < -1, A (n = 33)		-2 < T < -1, A+R (n = 37)		T ≥ -1, A (n = 50)
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Age, years	65.7	7.8	64.5	9.2	62.6	8.5	62.0	7.7
Height, cm	158.3	6.7	154.2	28.0	156.6	27.0	161.7	5.4
Weight, kg	69.6	11.2	70.5	12.4	70.6	9.6	78.2	11.3
BMD LS value	0.75	0.10	0.93	0.10	0.99	0.11	1.10	0.10
BMD HP value	0.72	0.10	0.79	0.09	0.79	0.08	0.91	0.12
	Number	Percentage	Number	Percentage	Number	Percentage	Number	Percentage
ECOG status
0	82	88.17	27	81.82	34	91.89	46	92.00
1	11	11.83	6	18.18	3	8.11	4	8.00
Fracture history
No	86	92.47	32	96.97	35	94.59	44	88.00
Yes^a	3	3.23	0	0.0	1	2.70	3	6.00
Not reported	4	4.30	1	3.03	1	2.70	3	6.00

^aTraumatic fractures only; between 3 to 56 years before enrollment in the study; none in the hip (HP) or lumbar spine (LS). A, anastrozole; BMD, bone mineral density; ECOG, Eastern Cooperative Oncology Group; R, risedronate; SD, standard deviation; T, T-score.

ISSN: 1465-542X